Literature DB >> 25994249

D-dimer for prediction of long-term outcome in cryptogenic stroke patients with patent foramen ovale.

Young Dae Kim, Dongbeom Song, Hyo Suk Nam, Kijeong Lee, Joonsang Yoo, Geu-Ru Hong, Hye Sun Lee, Chung Mo Nam, Ji Hoe Heo1.   

Abstract

Patent foramen ovale (PFO) is a potential cause of cryptogenic stroke, given the possibility of paradoxical embolism from venous to systemic circulation. D-dimer level is used to screen venous thrombosis. We investigated the risk of embolism and mortality according to the presence of PFO and D-dimer levels in cryptogenic stroke patients. A total of 570 first-ever cryptogenic stroke patients who underwent transesophageal echocardiography were included in this study. D-dimer was assessed using latex agglutination assay during admission. The association of long-term outcomes with the presence of PFO and D-dimer levels was investigated. PFO was detected in 241 patients (42.3 %). During a mean 34.0 ± 22.8 months of follow-up, all-cause death occurred in 58 (10.2 %) patients, ischaemic stroke in 33 (5.8 %), and pulmonary thromboembolism in 6 (1.1 %). Multivariate Cox regression analysis showed that a D-dimer level of > 1,000 ng/ml was an independent predictor for recurrent ischaemic stroke in patients with PFO (hazard ratio 5.341, 95 % confidence interval 1.648-17.309, p=0.005), but not in those without PFO. However, in patients without PFO, a D-dimer level of > 1,000 ng/ml was independently related with all-cause mortality. The risk of pulmonary thromboembolism tended to be high in patients with high D-dimer levels, regardless of PFO. Elevated D-dimer levels in cryptogenic stroke were predictive of the long-term outcome, which differed according to the presence of PFO. The coexistence of PFO and a high D-dimer level increased the risk of recurrent ischaemic stroke. The D-dimer test in cryptogenic stroke patients may be useful for predicting outcomes and deciding treatment strategy.

Entities:  

Keywords:  Cerebrovascular diseases; patent foramen ovale; stroke/prevention; thrombosis

Mesh:

Substances:

Year:  2015        PMID: 25994249     DOI: 10.1160/TH14-12-1040

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Ovarian Cancer Presenting as Cryptogenic Stroke from Patent Foramen Ovale.

Authors:  Bindu R Potugari; Priyanka Priyanka; Sarah D Komanapalli; Richard J Mercier
Journal:  Clin Med Res       Date:  2019-07-19

2.  Impact of D-dimer levels for short-term or long-term outcomes in cryptogenic stroke patients.

Authors:  Tomohisa Nezu; Takaya Kitano; Satoshi Kubo; Junichi Uemura; Shinji Yamashita; Takeshi Iwanaga; Takeshi Inoue; Naohisa Hosomi; Hirofumi Maruyama; Masayasu Matsumoto; Kazumi Kimura; Yoshiki Yagita
Journal:  J Neurol       Date:  2018-01-25       Impact factor: 4.849

Review 3.  Patent Foramen Ovale and Stroke-Current Status.

Authors:  Oh Young Bang; Mi Ji Lee; Sookyung Ryoo; Suk Jae Kim; Ji Won Kim
Journal:  J Stroke       Date:  2015-09-30       Impact factor: 6.967

4.  Association Between D-dimer and Early Adverse Events in Patients With Acute Type A Aortic Dissection Undergoing Arch Replacement and the Frozen Elephant Trunk Implantation: A Retrospective Cohort Study.

Authors:  Liu Tong; Jun Zheng; You-Cong Zhang; Kai Zhu; Hui-Qiang Gao; Kai Zhang; Xiu-Feng Jin; Shang-Dong Xu
Journal:  Front Physiol       Date:  2020-01-21       Impact factor: 4.566

Review 5.  Update on Biomarkers Associated to Cardioembolic Stroke: A Narrative Review.

Authors:  Ana Catarina Fonseca; Pedro Coelho
Journal:  Life (Basel)       Date:  2021-05-17

6.  A Systematic Review of the Predictive Value of Plasma D-Dimer Levels for Predicting Stroke Outcome.

Authors:  Peng Zhang; Chun Wang; Junhua Wu; Shiliang Zhang
Journal:  Front Neurol       Date:  2021-07-06       Impact factor: 4.003

7.  A Bayesian Network Model for Predicting Post-stroke Outcomes With Available Risk Factors.

Authors:  Eunjeong Park; Hyuk-Jae Chang; Hyo Suk Nam
Journal:  Front Neurol       Date:  2018-09-07       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.